Literature DB >> 6408008

Studies of lung infections caused by Pseudomonas aeruginosa in mice treated with cyclophosphamide.

P Mayer, H Walzl.   

Abstract

An experimental Pseudomonas aeruginosa lung infection was induced by aerosol exposure in mice which had been pretreated with cyclophosphamide. A single dose of 200 mg/kg cyclophosphamide resulted in leukopenia which lasted for three days. At the lowest PMN levels, the mice were exposed to aerosols containing varying doses of bacteria. The survival time of the mice and the number of viable bacteria in their lungs were determined. A dramatic rise in the viable counts of Pseudomonas organisms was found between 18 and 24 hours after infection. Mice which had not been pretreated with cyclophosphamide remained healthy and did not show any lung lesions. The number and phagocytic function of the alveolar macrophages remained unaltered after cyclophosphamide treatment. Thus, PMNs seem to play an important role in the lung's early defence mechanisms against Pseudomonas aeruginosa. This animal model could be of use in evaluating additional therapies for lung infections caused by Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408008     DOI: 10.1007/BF01641073

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  A sensitive and reproducible assay for the quantitation of erythrophagocytosis and its correlation with reduction in tritiated thymidine uptake in a tumor target cell system modified by immunoenhancing or immunosuppressive agents.

Authors:  M E Scheetz; L J Thomas; D K Allemenos
Journal:  Immunol Commun       Date:  1976

2.  Alveolobronchiolar transport mechanisms.

Authors:  G M Green
Journal:  Arch Intern Med       Date:  1973-01

3.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

4.  Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations.

Authors:  J E Balow; D L Hurley; A S Fauci
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

5.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

6.  Effect of cyclophosphamide on the immune response to Pseudomonas aeruginosa in mice.

Authors:  C L Pierson; A G Johnson; I Feller
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

7.  The effect of a protein-bound polysaccharide from Coriolus versicolor on immunological parameters and experimental infections in mice.

Authors:  P Mayer; J Drews
Journal:  Infection       Date:  1980       Impact factor: 3.553

8.  Pulmonary alveolar macrophage. Defender against bacterial infection of the lung.

Authors:  E Goldstein; W Lippert; D Warshauer
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

9.  THE ROLE OF THE ALVEOLAR MACROPHAGE IN THE CLEARANCE OF BACTERIA FROM THE LUNG.

Authors:  G M GREEN; E H KASS
Journal:  J Exp Med       Date:  1964-01-01       Impact factor: 14.307

10.  Origin, Kinetics, and characteristics of pulmonary macrophages in the normal steady state.

Authors:  A B van oud Alblas; R van Furth
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

View more
  2 in total

1.  Effect of cyclophosphamide on the candidacidal activity of rabbit peritoneal macrophages.

Authors:  D Kotulová; M Zalkovicová; J Stefanovic
Journal:  Folia Microbiol (Praha)       Date:  1988       Impact factor: 2.099

2.  Replication rate of Pseudomonas aeruginosa in the murine lung.

Authors:  D O Sordelli; M C Cerquetti; A M Hooke
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.